Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

2026-525309-11-00 · tracked via the Priya Life Science EU tracker

Sponsor

Antaros Medical AB

Sponsor type

Pharmaceutical company

Therapeutic area

Diagnosis

Decision date

11/03/2026

Enrollment target

Sites

Sweden

Condition studied

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525309-11-00 on CTIS ↗ ← All trials in the EU